+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia



Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia



Journal of Clinical Lipidology 2(6): 426-435



Co-administration of a fibrate and statin is an effective treatment option for patients with multiple lipid abnormalities, yet adequate long-term safety and efficacy data are lacking. To evaluate the long-term safety and efficacy of fenofibric acid combined with statins in adults with mixed dyslipidemia. Three large, 12-week, phase three, double-blind, randomized, controlled trials evaluated fenofibric acid 135 mg combined with a low- or moderate-dose statin compared to fenofibric acid or statin monotherapy, and a subsequent 52-week open-label extension study evaluated fenofibric acid 135 mg combined with moderate-dose statin (rosuvastatin 20 mg, simvastatin 40 mg, or atorvastatin 40 mg). This prespecified analysis integrated results from these studies to assess the long-term safety and efficacy of combination therapy. Across the controlled studies and the extension study, 2201 patients received at least one dose of fenofibric acid + statin for a median duration of 364 days. The most common adverse events were headache, upper respiratory tract infection, nasopharyngitis, and back pain, with the incidence of all adverse events being similar across all combination therapy treatment groups. Rhabdomyolysis or treatment-related death was not reported in any group. Combination therapy resulted in sustained improvements in multiple lipid parameters, including triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, and high-sensitivity C-reactive protein. Long-term fenofibric acid + statin combination therapy was generally well tolerated and resulted in comprehensive and sustained improvements in multiple lipid parameters in adults with mixed dyslipidemia.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054171730

Download citation: RISBibTeXText

PMID: 21291776

DOI: 10.1016/j.jacl.2008.10.001


Related references

Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Current Medical Research and Opinion 27(5): 1067-1078, 2011

Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies. Journal of Clinical Lipidology 3(2): 125-137, 2009

One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response. American Journal of Cardiovascular Drugs 12(2): 117-125, 2012

Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. American Journal of Cardiology 103(4): 515-522, 2009

Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia. American Heart Journal 160(4): 759-766, 2010

P296 Effects Of Fenofibric Acid In Combination With Statin Therapy On Low-Density Lipoprotein Particle Size In Patients With Mixed Dyslipidemia. Atherosclerosis Suppl.s 11(2): 79-80, 2010

Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study. Cardiovascular Drugs and Therapy 24(5-6): 421-428, 2010

Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 204(1): 208-215, 2009

Abstract: 517 Efficacy And Safety Of Fenofibric Acid In Combination With Atorvastatin And Ezetimibe In Patients With Mixed Dyslipidemia: A Phase 3 Study. Atherosclerosis Suppl.s 10(2): e262-e263, 2009

Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study. American Heart Journal 157(1): 195-203, 2009

Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. Vascular Health and Risk Management 6: 351-362, 2010

Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. American Journal of Cardiovascular Drugs 10(2): 73-84, 2010

Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia. American Journal of Cardiovascular Drugs 9(6): 401-409, 2009

Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides. Cardiovascular Drugs and Therapy 25(1): 59-67, 2011

Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: a pooled analysis of controlled studies. Journal of Clinical Lipidology 6(6): 534-544, 2013